Mineralys Therapeutics (MLYS) Profit After Tax (2022 - 2026)

Mineralys Therapeutics has reported Profit After Tax for 5 years, with the latest figure at -$39.3 million in Q1 2026.

• Quarterly Profit After Tax rose 6.9% year-over-year to -$39.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$151.8 million (up 19.48% YoY) and the FY2025 annual result came in at -$154.7 million, up 13.0% from the prior year.
• Profit After Tax retreated to -$39.3 million in Q1 2026 per MLYS's latest filing, from -$32.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$6.5 million in Q2 2022 and troughed at -$56.3 million in Q3 2024.
• A 5-year average of -$27.9 million and a median of -$31.5 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax plunged 240.82% in 2023, then soared 34.45% in 2025.
• Over 5 years, Profit After Tax stood at -$9.1 million in 2022, then sank by 168.81% to -$24.4 million in 2023, then tumbled by 100.69% to -$48.9 million in 2024, then surged by 34.04% to -$32.3 million in 2025, then fell by 21.74% to -$39.3 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$39.3 million, -$32.3 million, and -$36.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.